Cite

HARVARD Citation

    Iede, K. et al. (2022). Optimal Relative Dose Intensity in the First 4 Weeks During Nab-Paclitaxel Plus Gemcitabine for Older Patients With Advanced Pancreatic Cancer in Japan. Pancreas. 51 (1), pp. e4-e6. [Online]. 
  
Back to record